The pharmacology of meropenem, a new carbapenem antibiotic.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaApplication of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionGenetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibioticsPopulation pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilmsComparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patientsSynergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.Pharmacodynamic optimization of beta-lactams in the patient care setting.Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusionsProtein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.Antibiotics and renal branching morphogenesis: comparison of toxicities.Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem.Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study.Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.Maximally effective dosing regimens of meropenem in patients with septic shock.Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli.Inhibition of a cold-active alkaline phosphatase by imipenem revealed by in silico modeling of metallo-β-lactamase active sites.
P2860
Q22241905-5E278F86-F0D9-4539-A867-DA734C6B0337Q26753831-37500A46-E480-483E-A969-FA75D0FF8727Q28493162-686586FF-07C5-488F-97F3-6DBF7C35DBD7Q30316322-1219497B-065C-4C0A-9E95-80A801ECBA36Q33770046-5E8E1527-294D-47BC-BF38-737BB60BAFE1Q35076815-3FF8CCFC-158E-4C4A-A67F-4FC230966AC6Q35076958-D3B1BF24-E500-4AFA-B647-40CFD015D52BQ36200010-3CE52983-3D68-4C61-B992-D0C8DC00841DQ37120024-4E1D899B-D1DD-4B1A-BB84-F4E560CF198CQ37169843-8F6ACD4A-0E5E-43F5-964F-379D1FBB612FQ37247635-8301AFBA-3B28-4E56-AE53-D1633EC146D5Q37335840-D2350A63-4B05-43C4-80CD-9B72501A9760Q37544589-E26321DC-25E1-4B34-9DBF-6AD513A6DB05Q38244221-91846DA0-1FEC-4623-9074-C91C8618F7FDQ38749988-19A0A9CF-0D13-4CAE-934E-BA3F98EF6FC3Q38962138-C7053143-3183-4A6B-B46E-DF7C70DAC9FEQ40306198-DBB0723D-98BC-4037-83CA-AF25880D55BBQ40346786-D1CDAE64-CEF5-4B10-8D77-967371E6DEB6Q40367930-AB5D2BA5-45EE-4710-9827-7842E41006B2Q40389407-6554B3CC-D6D2-40B5-862F-D20C88649F5AQ40452947-9501532E-D83B-4CBE-A24E-0FC37442720BQ40903305-F5A01E47-3B15-4E67-B0E7-A182608B3057Q42654588-9A096372-CB2B-4E3E-9433-3E1FB807C313Q43800807-8F695D9A-8A50-4DFE-B664-3D100E659765Q44114518-20C3B28B-21F7-465E-B97F-E649E8E3D502Q46882759-366E2F09-1194-4F60-836E-4FEC99FD7F32Q47624900-A424108D-33AE-42FA-9B11-58C6F45E7D2EQ48144933-98ED354C-2FF6-48A6-BE39-E43E07CEA2EDQ50044377-E5903749-B691-4B42-9FA1-208122E237ECQ53797688-73778BD2-FB45-49BB-A04E-1A311F4649EAQ54327863-1EC1BBEF-2B59-4DC7-AAD0-A807845552F2
P2860
The pharmacology of meropenem, a new carbapenem antibiotic.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The pharmacology of meropenem, a new carbapenem antibiotic.
@en
type
label
The pharmacology of meropenem, a new carbapenem antibiotic.
@en
prefLabel
The pharmacology of meropenem, a new carbapenem antibiotic.
@en
P1476
The pharmacology of meropenem, a new carbapenem antibiotic.
@en
P2093
P304
P356
10.1093/CLINIDS/24.SUPPLEMENT_2.S266
P407
P478
24 Suppl 2
P577
1997-02-01T00:00:00Z